Other languages Firebrick Pharma Limited

Equities

FRE

AU0000197352

Market Closed - Australian S.E. Other stock markets 01:53:36 2024-06-07 am EDT			5-day change	1st Jan Change
0.056 ^AUD	0.00%		-6.67%	+12.00%

May. 23	Firebrick Pharma Obtains Nasodine Composition Patent in South Africa	MT
May. 17	Firebrick Pharma Raises AU$800,000 via Placement	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Firebrick Pharma Obtains Nasodine Composition Patent in South Africa	May. 22
Firebrick Pharma Phase 2 Covid-19 Trial Published in Laryngoscope Journal	Apr. 03
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 28
Firebrick Pharma to Release Shares from Escrow; Shares Rise 4%	Jan. 11
Firebrick Pharma Withdraws Appeal Against Regulator's Decision Over Nasodine Nasal Spray	Dec. 27
Firebrick Pharma's Nasodine Nasal Spray COVID-19 Patent Granted in South Africa	Nov. 29
Firebrick Pharma Receives AU$1.8 Million R&D Tax Rebate	23-10-31
Firebrick Says Independent Probe Into Nasodine Trial Results Did Not Find Errors	23-10-04
Firebrick Pharma's Cold Medication Fails Phase III Trial	23-09-13
Firebrick Pharma Limited Announces That Trial Statisticians Have Completed Their Efficacy Analysis of the Headline Results in the Phase 3 Trial of Nasodine® Nasal Spray as A Treatment for the Common Cold	23-09-12
Firebrick Pharma Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29
Firebrick Pharma Completes Enrollment for Cold Treatment Trial; Shares Soar 17%	23-08-09
Firebrick Pharma Raises AU$1 Million From Share Placement; Shares Slump 10%	23-04-30
Firebrick Pharma Resumes Phase Three Trial for Cold Medication; Shares Jump 8%	23-03-20
Firebrick Pharma Limited Announces Resume of Phase 3 Clinical Trial of Nasodine Nasal Spray	23-03-20
Firebrick Pharma Files Pediatric Investigation Plan in Europe for Common Cold Treatment	23-02-21
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-17
Firebrick Pharma Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-17
Firebrick Pharma Identifies New Indication for Nasal Spray Product	23-01-18
Australian Shares Erase Early Gains as Profit-Taking Weighs Down Financial Counters	22-11-14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Firebrick Pharma Limited

Equities

FRE

AU0000197352

Other languages

Filters